ArticleScientific reports2025
Biochanin A prevents neurodegeneration and oxidative stress in a kainic acid model of epilepsy by activating the PI3K/Akt/Nrf2 signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting oxidative stress pathways in epilepsy: mechanistic insights into the role of ascorbic acid.Molecular biology reports · 2026Review
- Neuroprotective effects ofBiomedical reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epilepsy is a serious neurodegenerative disorder, which affects approximately 50 million people worldwide. Growing evidence indicates that oxidative stress caused by an excessive production of free radicals is considered one of the etiologies of epilepsy. Several studies have demonstrated that neurotoxicity-induced oxidative stress leads to neuronal cell death and seizure severity. In this study, we investigated the possible effects of biochanin A (BA), a natural isoflavone containing antioxidant and neuroprotective activities, in a mouse model of epilepsy, induced by an intraperitoneal injection of kainic acid (KA). The administration of KA produced severe seizure activity, and a decrease in memory function. Histological studies following KA injection revealed significant neurodegeneration, astrocyte dysfunction, and microglia activation in CA1, CA3, and hilus of the hippocampus. Moreover, KA administration exhibited an increase in caspase-3, a decrease in antioxidative enzyme levels, and downregulation of the PI3K/Akt/Nrf2 signaling pathway. Conversely, BA treatment significantly increased seizure threshold and memory function. In addition, BA treatment reduced neuronal death, restored astrocyte function, and suppressed microglia activation in CA1, CA3, and hilus. The BA-mediated neuroprotection was accompanied by the significant upregulation of a crucial cellular pathway particularly related to the antioxidant defense system and cell survival, the PI3K/Akt/Nrf2 signaling pathway, thereby increasing antioxidant enzyme levels (GSH, SOD, CAT) and reducing neuronal death. Taken together, our results suggest that BA possesses a neuroprotective effect through bolstering antioxidant defense mechanisms and activating neuronal survival. Thus, BA could be a possible pharmacological agent for the amelioration of epilepsy or other neurodegenerative diseases where oxidative stress is a key factor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.